The California Institute for Regenerative Medicine approved a new $100 million program aimed at accelerating platform-based in vivo genetic therapies for rare diseases. The Rare Disease Acceleration Platform and Innovation and Delivery (RAPID) initiative will fund projects from IND-enabling work through first‑in‑human trials and prioritize approaches that can scale across multiple indications. CIRM framed RAPID as a strategic shift away from one‑off programs toward reusable platforms, citing recent successes in personalized CRISPR treatments. CIRM leaders emphasized the need for regulatory alignment and manufacturing strategies that support broader impact across thousands of rare disorders.